← Capabilities
- International families
- 76k2015 to 2024
- Leading country
- United States3.2× the next
- All families
- 134khome filings included
- Over five years
- Rising2020 to 2024 against the five before
Year by year
Patent families by country of origin and the year of the earliest filing, 2000 to 2025; 2025 is a part year, still filling in. International families are those for which protection was sought beyond one country.
Volume
International patent families in the capability, by the year of the earliest filing.
Source: Global Institute for National Capability (GINC), 2026. Underlying patents from 107 patent offices, IFI CLAIMS and Google
Share by country
Each country's share of the year's international families, in per cent: the capability's five largest countries of origin, 2015 to 2024, and the rest of the world.
Source: Global Institute for National Capability (GINC), 2026. Underlying patents from 107 patent offices, IFI CLAIMS and Google
Country leaderboard
International patent families, 2015 to 2024, by country of origin. Growth compares the latest five full years with the five before.
Ten largest
United States
China
Japan
South Korea
Germany
United Kingdom
France
Switzerland
Canada
Netherlands
35,382
11,223
4,471
4,072
2,767
2,633
2,265
2,190
1,273
962
| 2000 to 2025 | ||||||
|---|---|---|---|---|---|---|
| 1 | United States | 35,382 | 46.5% | 1.3× | 41,041 | |
| 2 | China | 11,223 | 14.7% | 3.2× | 54,255 | |
| 3 | Japan | 4,471 | 5.9% | 1.1× | 5,997 | |
| 4 | South Korea | 4,072 | 5.3% | 1.4× | 7,989 | |
| 5 | Germany | 2,767 | 3.6% | 1.1× | 2,981 | |
| 6 | United Kingdom | 2,633 | 3.5% | 1.1× | 2,830 | |
| 7 | France | 2,265 | 3.0% | 1.0× | 2,395 | |
| 8 | Switzerland | 2,190 | 2.9% | 1.0× | 2,330 | |
| 9 | Canada | 1,273 | 1.7% | 1.2× | 1,419 | |
| 10 | Netherlands | 962 | 1.3% | 1.2× | 1,013 | |
| 11 | Belgium | 945 | 1.2% | 1.1× | 992 | |
| 12 | Israel | 817 | 1.1% | 1.1× | 879 | |
| 13 | Australia | 783 | 1.0% | 1.1× | 826 | |
| 14 | Taiwan | 728 | 1.0% | 1.1× | 1,056 | |
| 15 | Sweden | 580 | 0.8% | 1.5× | 619 | |
| 16 | Denmark | 575 | 0.8% | 1.3× | 627 | |
| 17 | Spain | 566 | 0.7% | 1.5× | 611 | |
| 18 | Italy | 555 | 0.7% | 1.3× | 614 | |
| 19 | Singapore | 534 | 0.7% | 1.7× | 560 | |
| 20 | India | 433 | 0.6% | 1.5× | 479 | |
| 21 | Ireland | 355 | 0.5% | 0.8× | 382 | |
| 22 | Russia | 212 | 0.3% | 1.1× | 949 | |
| 23 | Norway | 174 | 0.2% | 1.0× | 184 | |
| 24 | Austria | 168 | 0.2% | 1.1× | 175 | |
| 25 | Türkiye | 139 | 0.2% | 1.9× | 209 | |
| 26 | Brazil | 123 | 0.2% | 1.1× | 335 | |
| 27 | Poland | 98 | 0.1% | 1.5× | 190 | |
| 28 | Finland | 96 | 0.1% | 1.1× | 101 | |
| 29 | Portugal | 95 | 0.1% | 1.1× | 103 | |
| 30 | Cayman Islands | 92 | 0.1% | 0.7× | 118 | |
| 31 | Hong Kong | 68 | 0.1% | 2.6× | 102 | |
| 32 | Czechia | 54 | 0.1% | 1.2× | 68 | |
| 33 | Mexico | 50 | 0.1% | 0.7× | 147 | |
| 34 | New Zealand | 41 | 0.1% | 0.9× | 49 | |
| 35 | Luxembourg | 39 | 0.1% | 0.2× | 42 | |
| 36 | South Africa | 35 | 0.0% | 0.9× | 38 | |
| 37 | Hungary | 32 | 0.0% | 1.5× | 44 | |
| 38 | Malaysia | 21 | 0.0% | 0.3× | 44 | |
| 39 | Saudi Arabia | 15 | 0.0% | 1.1× | 44 | |
| 40 | Liechtenstein | 5 | 0.0% | 0.3× | 5 |
Applicants
The largest applicants by international patent families, 2015 to 2024: across the world, then within each of the five countries with the most families in Advanced Therapeutics, Vaccines & Medical Countermeasures. Names are as held in the source and are not consolidated across subsidiaries.
Global
76,135 international families
UNIV CALIFORNIA · United States
INST NAT SANTE RECH MED · France
HOFFMANN LA ROCHE · Switzerland
UNIV TEXAS · United States
REGENERON PHARMA · United States
UNIV LELAND STANFORD JUNIOR · United States
1,233
992
769
696
685
585
United States
35,382 international families
UNIV CALIFORNIA
UNIV TEXAS
REGENERON PHARMA
UNIV LELAND STANFORD JUNIOR
UNIV PENNSYLVANIA
US HEALTH
1,215
672
665
572
532
472
China
11,223 international families
JIANGSU HENGRUI MEDICINE CO
Shanghai hengrui pharmaceutical co ltd
JIANGSU HENGRUI PHARMACEUTICALS CO LTD
INNOVENT BIOLOGICS SUZHOU CO LTD
SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD
BIO THERA SOLUTIONS LTD
207
168
166
123
111
101
Japan
4,471 international families
UNIV OSAKA
UNIV TOKYO
CHUGAI PHARMACEUTICAL CO LTD
UNIV KYOTO
TAKEDA PHARMACEUTICALS CO
DAIICHI SANKYO CO LTD
221
211
198
176
154
153
South Korea
4,072 international families
SEOUL NAT UNIV R&DB FOUNDATION
UNIV KOREA RES & BUS FOUND
UNIV YONSEI IACF
KOREA ADVANCED INST SCI & TECH
KOREA RES INST BIOSCIENCE & BIOTECHNOLOGY
CATHOLIC UNIV KOREA IND ACADEMIC COOPERATION FOUNDATION
207
102
102
101
83
81
Germany
2,767 international families
BioNTech SE
BOEHRINGER INGELHEIM INT
IMMATICS BIOTECHNOLOGIES GMBH
MERCK PATENT GMBH
DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS
DEUTSCHES KREBSFORSCH
221
140
125
97
72
69
Similar capabilities
The nine capabilities that share the most international patent families with Advanced Therapeutics, Vaccines & Medical Countermeasures, 2015 to 2024: the families counted in both as a share of those counted in either. Each card shows its five largest countries.
Critical Technology
Synthetic Biology & Genetic Engineering
36.4% shared · 40,220 families in both
United States
China
Japan
South Korea
Germany
31,378
14,103
6,820
3,970
2,703
Human Capital
Physical Health & Longevity
34.5% shared · 72,198 families in both
United States
China
South Korea
Japan
Germany
77,497
32,383
14,190
14,101
7,671
Critical Technology
Biomanufacturing
20.1% shared · 24,652 families in both
United States
China
Japan
South Korea
Germany
25,142
10,048
9,595
4,747
3,497
Human Capital
Nutrition & Preventive Health
10.6% shared · 10,290 families in both
United States
South Korea
China
Japan
Switzerland
7,952
5,251
3,446
3,403
1,203
Critical Technology
Genomics & Biological Data
5.2% shared · 5,758 families in both
United States
China
Japan
South Korea
Germany
17,818
5,444
3,003
2,851
1,616
Human Capital
Public Health Functions
4.3% shared · 3,706 families in both
United States
China
Japan
South Korea
Germany
5,511
1,782
1,627
909
600
Strategic Infrastructure
Public Health & Laboratories
3.3% shared · 3,080 families in both
United States
Japan
China
Germany
South Korea
7,163
3,632
2,667
1,475
1,202
Critical Technology
Nuclear Medicine & Radioisotope Technologies
2.2% shared · 1,911 families in both
United States
China
Japan
Germany
South Korea
4,153
2,013
1,410
792
720
Production & Innovation
Agrifood & Primary Production
2.1% shared · 4,278 families in both
United States
Japan
China
Germany
South Korea
28,708
17,669
15,613
10,229
9,737
Crosswalk
How Advanced Therapeutics, Vaccines & Medical Countermeasures is matched to the patent classifications. The entries below were chosen for it; each stands for itself and everything beneath it in the scheme, 638 Cooperative entries in all. A patent family counts when any of its codes, in either scheme and at any office, falls under one of them. Codes since retired are placed under the entries that replaced them.
| Entry | Title in the scheme | Why it is chosen | CPC codes | IPC codes | Documents |
|---|---|---|---|---|---|
| A61K39/00 | Medicinal preparations containing antigens or antibodies | Vaccines and antibody medicines | 376 | 68 | 2,481,082 |
| C07K16/00 | Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies | Antibodies | 157 | 59 | 1,512,140 |
| A61K48/00 | Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy | Gene therapy | 12 | 1 | 287,790 |
| A61K40/00 | Cellular immunotherapy | Cellular immunotherapy | 134 | 26 | 442,425 |
| A61K35/17 | Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes | Lymphocyte and T-cell therapies | 1 | 1 | 50,794 |
| A61K35/28 | Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells | Stem cell therapies | 1 | 1 | 44,147 |
| A61K35/76 | Viruses; Subviral particles; Bacteriophages | Therapeutic viruses and bacteriophages | 6 | 6 | 77,092 |
| A61K47/68 | Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment | Antibody-drug conjugates | 55 | 1 | 347,148 |
| A61K31/7088 | Compounds having three or more nucleosides or nucleotides | Nucleic acid medicines, including RNA therapeutics | 7 | 7 | 208,959 |
CPC and IPC codes are the codes in use on patent documents, at any office, that fall under the entry. Documents is the larger of the two schemes' counts of documents carrying one of them. An entry with no IPC codes can be told apart only in the Cooperative scheme.
The Cooperative codes in use that count towards Advanced Therapeutics, Vaccines & Medical Countermeasures: 749 codes on 5,398,075 documents. The 150 most used are listed; the full list is in the cpc-to-capability.csv download.
| Code | Title | Under entry | How placed | Documents |
|---|---|---|---|---|
| A61K2039/505 | Medicinal preparations containing antigens or antibodies comprising antibodies | A61K39/00 | In the scheme | 369,886 |
| A61K39/395 | Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum | A61K39/00 | In the scheme | 140,787 |
| A61K48/00 | Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy | A61K48/00 | In the scheme | 137,869 |
| A61K39/00 | Medicinal preparations containing antigens or antibodies | A61K39/00 | In the scheme | 132,546 |
| C07K16/18 | Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans | C07K16/00 | In the scheme | 120,544 |
| A61K39/3955 | Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines | A61K39/00 | In the scheme | 115,003 |
| A61K39/12 | Viral antigens | A61K39/00 | In the scheme | 114,170 |
| C07K16/28 | Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants | C07K16/00 | In the scheme | 99,219 |
| A61K2039/545 | Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule | A61K39/00 | In the scheme | 88,876 |
| A61K40/11 | T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells | A61K40/00 | In the scheme | 85,541 |
| C07K16/00 | Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies | C07K16/00 | In the scheme | 81,754 |
| C07K16/2803 | Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily | C07K16/00 | In the scheme | 77,103 |
| C07K16/30 | Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells | C07K16/00 | In the scheme | 72,922 |
| A61K39/39 | Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants | A61K39/00 | In the scheme | 70,983 |
| A61K39/39558 | Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens | A61K39/00 | In the scheme | 59,978 |
| C07K16/2818 | Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152 | C07K16/00 | In the scheme | 59,968 |
| A61K31/7088 | Compounds having three or more nucleosides or nucleotides | A61K31/7088 | In the scheme | 58,635 |
| A61K31/713 | Double-stranded nucleic acids or oligonucleotides | A61K31/7088 | In the scheme | 57,643 |
| C07K16/40 | Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes | C07K16/00 | In the scheme | 56,544 |
| A61K48/005 | Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered | A61K48/00 | In the scheme | 55,022 |
| C07K16/2863 | Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators | C07K16/00 | In the scheme | 53,474 |
| A61K47/6849 | Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant | A61K47/68 | In the scheme | 52,721 |
| A61K2039/53 | DNA (RNA) vaccination | A61K39/00 | In the scheme | 52,464 |
| A61K35/17 | Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes | A61K35/17 | In the scheme | 50,794 |
| A61K40/31 | Chimeric antigen receptors [CAR] | A61K40/00 | In the scheme | 50,750 |
| A61K2039/54 | Medicinal preparations containing antigens or antibodies characterised by the route of administration | A61K39/00 | In the scheme | 48,676 |
| C07K16/22 | Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators | C07K16/00 | In the scheme | 47,863 |
| A61K39/0011 | Cancer antigens | A61K39/00 | In the scheme | 47,219 |
| C07K16/32 | Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes | C07K16/00 | In the scheme | 47,136 |
| A61K2039/507 | Comprising a combination of two or more separate antibodies | A61K39/00 | In the scheme | 45,520 |
| C07K16/2896 | Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere | C07K16/00 | In the scheme | 44,486 |
| A61K35/28 | Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells | A61K35/28 | In the scheme | 44,147 |
| C07K16/2866 | Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons | C07K16/00 | In the scheme | 43,244 |
| C07K16/2809 | Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex | C07K16/00 | In the scheme | 43,121 |
| C07K16/2878 | Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 | C07K16/00 | In the scheme | 40,486 |
| C07K16/2827 | Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86 | C07K16/00 | In the scheme | 39,995 |
| A61K31/7105 | Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links | A61K31/7088 | In the scheme | 39,887 |
| A61K2039/70 | Multivalent vaccine | A61K39/00 | In the scheme | 36,357 |
| A61K2039/552 | Veterinary vaccine | A61K39/00 | In the scheme | 32,703 |
| A61K47/6851 | Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell | A61K47/68 | In the scheme | 31,333 |
| A61K2039/55505 | Inorganic adjuvants | A61K39/00 | In the scheme | 30,609 |
| A61K2039/55555 | Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers | A61K39/00 | In the scheme | 30,055 |
| A61K40/42 | Cancer antigens | A61K40/00 | In the scheme | 29,160 |
| A61K47/6803 | Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates | A61K47/68 | In the scheme | 28,682 |
| C07K16/244 | Interleukins [IL] | C07K16/00 | In the scheme | 27,734 |
| C07K16/2887 | Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20 | C07K16/00 | In the scheme | 27,228 |
| A61K47/6889 | Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment | A61K47/68 | In the scheme | 26,510 |
| A61K2039/55566 | Emulsions, e.g. Freund's adjuvant, MF59 | A61K39/00 | In the scheme | 26,328 |
| C07K16/468 | Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies | C07K16/00 | In the scheme | 25,286 |
| A61K2039/5256 | Virus expressing foreign proteins | A61K39/00 | In the scheme | 24,733 |
| A61K39/145 | Orthomyxoviridae, e.g. influenza virus | A61K39/00 | In the scheme | 24,057 |
| A61K2039/57 | Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 | A61K39/00 | In the scheme | 23,040 |
| A61K2039/5254 | Virus avirulent or attenuated | A61K39/00 | In the scheme | 22,652 |
| A61K39/39591 | Stabilisation, fragmentation | A61K39/00 | In the scheme | 22,480 |
| A61K40/4211 | CD19 or B4 | A61K40/00 | In the scheme | 22,310 |
| A61K2039/575 | Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response | A61K39/00 | In the scheme | 22,154 |
| C07K16/44 | Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids | C07K16/00 | In the scheme | 21,979 |
| C07K16/24 | Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons | C07K16/00 | In the scheme | 21,387 |
| A61K2039/572 | Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response | A61K39/00 | In the scheme | 21,257 |
| A61K39/385 | Haptens or antigens, bound to carriers | A61K39/00 | In the scheme | 21,206 |
| C07K16/241 | Tumor Necrosis Factors | C07K16/00 | In the scheme | 21,126 |
| A61K47/68 | Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment | A61K47/68 | In the scheme | 18,579 |
| A61K2039/55561 | CpG containing adjuvants; Oligonucleotide containing adjuvants | A61K39/00 | In the scheme | 18,553 |
| A61K40/32 | T-cell receptors [TCR] | A61K40/00 | In the scheme | 18,373 |
| A61K48/0058 | Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct | A61K48/00 | In the scheme | 18,155 |
| C07K16/46 | Hybrid immunoglobulins | C07K16/00 | In the scheme | 17,869 |
| A61K2039/5252 | Virus inactivated (killed) | A61K39/00 | In the scheme | 17,819 |
| A61K48/0075 | Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous | A61K48/00 | In the scheme | 17,473 |
| A61K47/68031 | Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin | A61K47/68 | In the scheme | 17,405 |
| A61K40/24 | Antigen-presenting cells [APC] | A61K40/00 | In the scheme | 17,395 |
| A61K2039/55511 | Organic adjuvants | A61K39/00 | In the scheme | 17,359 |
| A61K2039/5158 | Antigen-pulsed cells, e.g. T-cells | A61K39/00 | In the scheme | 17,262 |
| A61K2039/55516 | Proteins; Peptides | A61K39/00 | In the scheme | 16,268 |
| A61K35/76 | Viruses; Subviral particles; Bacteriophages | A61K35/76 | In the scheme | 16,120 |
| A61K2039/6037 | Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT] | A61K39/00 | In the scheme | 15,680 |
| A61K2039/5156 | Animal cells expressing foreign proteins | A61K39/00 | In the scheme | 15,440 |
| A61K2039/5258 | Virus-like particles | A61K39/00 | In the scheme | 15,304 |
| A61K40/15 | Natural-killer [NK] cells; Natural-killer T [NKT] cells | A61K40/00 | In the scheme | 15,276 |
| A61K39/39541 | Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells | A61K39/00 | In the scheme | 15,249 |
| A61K2039/585 | Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer | A61K39/00 | In the scheme | 15,160 |
| C07K16/3069 | Reproductive system, e.g. ovaria, uterus, testes, prostate | C07K16/00 | In the scheme | 15,101 |
| C07K16/2875 | Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154 | C07K16/00 | In the scheme | 15,099 |
| A61K47/6811 | Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin | A61K47/68 | In the scheme | 14,913 |
| A61K47/6855 | Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell | A61K47/68 | In the scheme | 14,243 |
| A61K2039/55 | Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies | A61K39/00 | In the scheme | 13,761 |
| C07K16/065 | Purification, fragmentation | C07K16/00 | In the scheme | 13,426 |
| A61K40/19 | Dendritic cells | A61K40/00 | In the scheme | 13,346 |
| A61K2039/543 | Mucosal route intranasal | A61K39/00 | In the scheme | 13,244 |
| C07K16/2833 | Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules | C07K16/00 | In the scheme | 13,236 |
| C07K16/283 | Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64 | C07K16/00 | In the scheme | 13,081 |
| A61K39/092 | Streptococcus | A61K39/00 | In the scheme | 12,989 |
| A61K2039/55572 | Lipopolysaccharides; Lipid A; Monophosphoryl lipid A | A61K39/00 | In the scheme | 12,934 |
| A61K39/21 | Retroviridae, e.g. equine infectious anemia virus | A61K39/00 | In the scheme | 12,911 |
| C07K16/26 | Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors | C07K16/00 | In the scheme | 12,691 |
| A61K31/711 | Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links | A61K31/7088 | In the scheme | 12,583 |
| A61K39/0008 | Antigens related to auto-immune diseases; Preparations to induce self-tolerance | A61K39/00 | In the scheme | 12,547 |
| A61K40/22 | Immunosuppressive or immunotolerising | A61K40/00 | In the scheme | 12,007 |
| A61K48/0041 | Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric | A61K48/00 | In the scheme | 11,874 |
| A61K48/0008 | Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition | A61K48/00 | In the scheme | 11,860 |
| A61K40/46 | Viral antigens | A61K40/00 | In the scheme | 11,843 |
| A61K2039/542 | Mucosal route oral/gastrointestinal | A61K39/00 | In the scheme | 11,754 |
| C07K16/2851 | Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 | C07K16/00 | In the scheme | 11,599 |
| A61K31/7125 | Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters | A61K31/7088 | In the scheme | 11,581 |
| A61K2039/55577 | Saponins; Quil A; QS21; ISCOMS | A61K39/00 | In the scheme | 11,394 |
| A61K48/0066 | Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid | A61K48/00 | In the scheme | 11,210 |
| C07K16/10 | RNA viruses | C07K16/00 | In the scheme | 10,808 |
| A61K2039/522 | Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated | A61K39/00 | In the scheme | 10,687 |
| A61K39/39533 | Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals | A61K39/00 | In the scheme | 10,609 |
| A61K39/215 | Coronaviridae, e.g. avian infectious bronchitis virus | A61K39/00 | In the scheme | 10,563 |
| A61K39/0005 | Vertebrate antigens | A61K39/00 | In the scheme | 10,341 |
| A61K47/68033 | Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine | A61K47/68 | In the scheme | 10,329 |
| C07K16/3061 | Blood cells | C07K16/00 | In the scheme | 10,195 |
| A61K39/095 | Neisseria | A61K39/00 | In the scheme | 10,034 |
| A61K39/02 | Bacterial antigens | A61K39/00 | In the scheme | 9,705 |
| A61K2039/5154 | Antigen presenting cells [APCs], e.g. dendritic cells or macrophages | A61K39/00 | In the scheme | 9,703 |
| C07K16/303 | Liver or Pancreas | C07K16/00 | In the scheme | 9,702 |
| A61K2039/523 | Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins | A61K39/00 | In the scheme | 9,494 |
| A61K2039/6031 | Proteins | A61K39/00 | In the scheme | 9,377 |
| A61K39/35 | Allergens | A61K39/00 | In the scheme | 9,369 |
| A61K2039/55522 | Cytokines; Lymphokines; Interferons | A61K39/00 | In the scheme | 9,295 |
| A61K40/10 | Cellular immunotherapy characterised by the cell type used | A61K40/00 | In the scheme | 9,174 |
| A61K39/08 | Clostridium, e.g. Clostridium tetani | A61K39/00 | In the scheme | 9,124 |
| A61K40/4202 | Receptors, cell surface antigens or cell surface determinants | A61K40/00 | In the scheme | 9,115 |
| A61K47/68037 | Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives | A61K47/68 | In the scheme | 9,057 |
| C07K16/3015 | Breast | C07K16/00 | In the scheme | 9,034 |
| A61K39/245 | Herpetoviridae, e.g. herpes simplex virus | A61K39/00 | In the scheme | 8,850 |
| C07K16/36 | Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors | C07K16/00 | In the scheme | 8,733 |
| C07K16/3046 | Stomach, Intestines | C07K16/00 | In the scheme | 8,684 |
| A61K31/712 | Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose | A61K31/7088 | In the scheme | 8,491 |
| A61K39/04 | Mycobacterium, e.g. Mycobacterium tuberculosis | A61K39/00 | In the scheme | 8,419 |
| A61K39/42 | Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral | A61K39/00 | In the scheme | 8,338 |
| A61K2039/525 | Virus | A61K39/00 | In the scheme | 8,316 |
| A61K35/761 | Adenovirus | A61K35/76 | In the scheme | 8,167 |
| A61K39/155 | Paramyxoviridae, e.g. parainfluenza virus | A61K39/00 | In the scheme | 8,164 |
| C07K16/005 | Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries | C07K16/00 | In the scheme | 7,944 |
| A61K40/4215 | Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30 | A61K40/00 | In the scheme | 7,823 |
| A61K47/6817 | Toxins | A61K47/68 | In the scheme | 7,767 |
| C07K16/3023 | Lung | C07K16/00 | In the scheme | 7,756 |
| A61K39/102 | Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus | A61K39/00 | In the scheme | 7,640 |
| A61K2039/521 | Bacterial cells; Fungal cells; Protozoal cells inactivated (killed) | A61K39/00 | In the scheme | 7,637 |
| C07K16/3007 | Carcino-embryonic Antigens | C07K16/00 | In the scheme | 7,496 |
| A61K40/416 | Antigens related to auto-immune diseases; Preparations to induce self-tolerance | A61K40/00 | In the scheme | 7,478 |
| A61K31/7115 | Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine | A61K31/7088 | In the scheme | 7,334 |
| C07K16/2869 | Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors | C07K16/00 | In the scheme | 7,332 |
| A61K40/421 | Immunoglobulin superfamily | A61K40/00 | In the scheme | 7,238 |
| A61K2039/627 | Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker | A61K39/00 | In the scheme | 7,211 |
| C07K16/3053 | Skin, nerves, brain | C07K16/00 | In the scheme | 7,121 |
| A61K48/0033 | Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric | A61K48/00 | In the scheme | 7,119 |
| C07K16/1145 | Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site | C07K16/00 | In the scheme | 7,107 |
| A61K47/6809 | Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin | A61K47/68 | In the scheme | 7,026 |
Match: Direct
The capability is itself a technology or a kind of physical system, and the classification names it. Antimicrobials have no clean entry: the anti-infective activity tags (A61P31) are too broad and include traditional remedies, so they are left out. The crosswalk is a first pass that nobody has reviewed.